-
Long-Term Survival after T-cell Lymphoblastic Lymphoma Treated with One Cycle of Hyper-CVAD Regimen
-
Il Hwan Ryu, In Sung Cho, Ah Jeong Ryu, Min Gyu Kim, Jae Woong Jeon, Joo Seok Kim, Jae Joon Lee, Ji Wook Choi, Dong Wook Kang
-
Cancer Res Treat. 2015;47(1):115-119. Published online August 25, 2014
-
DOI: https://doi.org/10.4143/crt.2013.122
-
-
 Abstract
 PDF PubReader ePub
- T-lymphoblastic lymphoma (T-LBL) is a rare form of aggressive non-Hodgkin’s lymphoma. The standard approach for management of T-LBL involves intensive multiagent chemotherapy regimens for induction and consolidation phases with central nervous system prophylaxis and a maintenance phase lasting 12-18 months. We report on a case of long-term survival after one cycle of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) and high-dose methotrexate. A 30-year-old woman diagnosed with T-LBL with a large mediastinal mass underwent one cycle of hyper-CVAD. Four days after the start of treatment, the mediastinal mass was markedly reduced. Treatment continued with one cycle of consolidation chemotherapy, comprising high-dose methotrexate and high-dose cytarabine. The patient then refused all further chemotherapeutic treatment. Seven years have passed without relapse.
-
Citations
Citations to this article as recorded by 
-
16,097
View
-
97
Download
-
3
Web of Science
-
4
Crossref
|
KCA
